Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
Authors' conclusion
In this study, the result suggested that tofacitinib therapy exerted a certain effect on skin manifestations, muscle manifestations, interstitial lung disease (ILD), calcinosis, as well as downgrade of medication.
Study context
- Population
- Patients in China diagnosed with refractory juvenile dermatomyositis (JDM) treated with tofacitinib for over 3 months
- Participants
- 88 patients
- Exposure
- Tofacitinib therapy, outcomes vs baseline
- Outcome
- Efficacy of tofacitinib in refractory JDM
- Follow-up
- Most recent
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Clinical complete response
nearly 50%
Tofacitinib monotherapy
6
Observational data: associations, not effects.
Further findings
Interstitial lung disease (ILD) well recovered on high-resolution CT (patients with ILD)
- Well recovered
- 60%
Calcinosis
- Reduction in size or number
- 75%
- Completely resolved
- 25%
Original publication
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China. Arthritis Res Ther. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →